No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC Liam Davenport May 11, 2026

https://www.medscape.com/viewarticle/no-survival-benefit-seen-adjuvant-atezolizumab-tnbc-2026a1000f20 Adding atezolizumab immunotherapy to capecitabine for the adjuvant treatment of triple-negative breast cancer (TNBC) in patients with residual disease after neoadjuvant chemotherapy does not offer a significant survival benefit, suggested a Korean trial. There was nevertheless a numerical improvement seen in both invasive disease-free and overall survival with atezolizumab plus capecitabine vs capecitabine alone, reaching a trend toward a benefit in patients with tumors positive for PD-L1 expression.